MarkASocinskiMD

Oncology • Orlando, FL

Physician

Join to view full profile

Dr. Socinski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Socinski's full profile

Already have an account?

Office
2501 N Orange Ave
Ste 689
Orlando, FL 32804
Phone+1 407-303-2024

Fax+1 407-303-2038
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1989
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1986
University of Vermont College of MedicineClass of 1984

Certifications & Licensure

FL State Medical License 2016 - 2026
NC State Medical License 1995 - 2017
PA State Medical License 2011 - 2016
VT State Medical License 1988 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 2
BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Nov 01
Unknown status
Phase 2
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Start of enrollment: 2005 May 31
Completed
Phase 2
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC Start of enrollment: 2004 May 01
Completed
Phase 2
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 Nov 01
Completed
Phase 3
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Start of enrollment: 2008 Dec 01
Terminated
Phase 1
Computed Tomography (CT) Perfusion Imaging of Lung Cancer Start of enrollment: 2009 Jun 01
Terminated
Not Applicable
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab Start of enrollment: 2010 Dec 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Start of enrollment: 2014 Apr 01
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical ...
Lee X Li, Ganessan Kichenadasse, Christos S Karapetis, Adel Shahnam, Ross A McKinnon, Andrew Rowland, Ashley M Hopkins, Michael J Sorich, Mark A Socinski> ;BMC Cancer. 2024 Mar 25
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Ea...
Wang, H., Shaverdashvili, K., Reyes, V., Mehta, D., Marsh, C., Waas, J., VanderWeele, R., Peracha, S., Liang, H., Socinski, M., Gerber, D., Dowell, J., Villaruz, L.> ;Eclinicalmedicine. 2023 Dec 1
1 citations
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin) in Patients with Non-squamous Non-small Cell Lung Cancer.
Joel S Owen, Russell J Rackley, Matthew A Hummel, Stefan Roepcke, Hannah Huang, Mark Liu, Tazeen A Idris, Sundara Moorthi Nainar Murugesan, Ashwani Marwah, Subramanian...> ;European Journal of Drug Metabolism and Pharmacokinetics. 2023 Nov 1
5 citations
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Bruna Pellini, Russell W Madison, Merrida A Childress, Shoshana T Miller, Ole Gjoerup, Jason Cheng, Richard S P Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David...> ;Clinical Cancer Research. 2023 Nov 14
1 citations
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Anika Mang, Wei Zou, Vinzent Rolny, Martin Reck, Daniel Cigoianu, Katja Schulze, Stefan Holdenrieder, Mark A Socinski, David S Shames, Birgit Wehnl, Namrata S Patil> ;Tumour Biology. 2024 Jan 1
3 citations
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J Swensen, David Spetzler, Wolfgang Michael Korn,...> ;Translational Oncology. 2023 Oct 1
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy.
Ticiana Leal, Mark A Socinski> ;Expert Review of Anticancer Therapy. 2023 Jul 24
5 citations
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M Wrangle, Ma...> ;Journal of Clinical Oncology. 2023 Sep 10
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Har...
J Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, Benjamin P Levy, Hossein Borghaei, Bruna Pellini, Michael R Costello, Jonathan E Dowell, Gene Finley, Chao H Huang,...> ;Clinical Lung Cancer. 2023 Nov 1
12 citations
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina Baik, Mirjana Wollner, Eric B Haura, Hirva Mamdani, Jonathan W Riess, Federico Cappuzzo, Marina C Garassino, Jo...> ;Journal of Thoracic Oncology. 2023 Aug 1
23 citations
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Zoe June F Assaf, Wei Zou, Alexander D Fine, Mark A Socinski, Amanda Young, Doron Lipson, Jonathan F Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabr...> ;Nature Medicine. 2023 Apr 1
3 citations
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Lee X Li, Federico Cappuzzo, Ignacio Matos, Mark A Socinski, Ashley M Hopkins, Michael J Sorich> ;The Oncologist. 2023 Apr 6
32 citations
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpo...
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Makoto Nishio, Tony S K Mok, Martin Reck, Gene G Finley, Monika D Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bara, Ho...> ;JAMA Oncology. 2023 Apr 1
4 citations
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Y Jin, Micha...> ;Clinical Cancer Research. 2023 Mar 14
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Luis E Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M Vanderwalde, Gilberto L...> ;Frontiers in Oncology. 2023 Jan 1
6 citations
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine.
Liza C Villaruz, Mark A Socinski, Jared Weiss> ;Frontiers in Oncology. 2023 Jan 1
1 citations
GEMSTONE-302: "If you keep doing the same thing you get the same result".
Jieying Liu, Tarek Mekhail, Mark A Socinski, Guo, M.> ;Chinese Clinical Oncology. 2022 Dec 1
3 citations
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jieying Liu, Ruoyu Miao, Zohaib Ahmed, James Yu, Jian Guan, Sarfraz Ahmad, Shuntai Zhou, Angela Grove, Manoucher Manoucheri, Mark A Socinski, Tarek Mekhail, Guo, M.> ;Journal of Immunotherapy. 2022 Sep 5
4 citations
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lu...
Byoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, Mark A Socinski, Timothy F Burns, Zarnie Lwin, Nuzhat Pathan, Wei Dong Ma, Joanna C Masters, Nandini Cossons, Keith Wi...> ;Expert Opinion on Investigational Drugs. 2022 Jul 1
68 citations
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan, Sylvia Hu, Young Kwang Chae, Ticiana A Leal, Jonathan E Dowell, Michaela L Tsai, Christophe...> ;Nature Medicine. 2022 May 1
47 citations
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy inmutated non-small cell lung cancer with,orcomutations: subgroup results from the phase III IMpowe...
Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony Sk Mok, Robert M Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David Shames, Meghn...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jieying Liu, Shuntai Zhou, James Yu, Zohaib Ahmed, Sarfraz Ahmad, Mark A Socinski, Tarek Mekhail, Vincent Hsu, Guo, M., Manoucheri, M.> ;SN Comprehensive Clinical Medicine. 2022 Jan 1
1 citations
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework.
Stephen V Liu, Misako Nagasaka, Victoria Stefaniak, Kristi Gruver, Yong Lin, David Ferry, Mark A Socinski, Li Zhang> ;Frontiers in Oncology. 2022 Jan 1
62 citations
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Xiuning Le, Robin Cornelissen, Marina Chiara Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V....> ;Journal of Clinical Oncology. 2021 Nov 29
6 citations
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donne...> ;Therapeutic Advances in Medical Oncology. 2021 Nov 18
Join now to see all

Journal Articles

Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Robert M Jotte, Mark A Socinski, The New England Journal of Medicine
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Liza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy

Lectures

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).
2019 ASCO Annual Meeting - 6/1/2019
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) bevacizumab (bev) vs chemo + bev in 1L nonsquamou...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Expanding Targets in Lung Cancer
Physicians' Education Resource, LLC, Chicago, Illinois - 6/2/2013
Join now to see all

Press Mentions

Low-Grade Immune-Related Adverse Events Linked to Prolonged Survival in NSCLCJune 5th, 2021
AdventHealth Central Florida Asks for 40K Vaccines from State, Gets 500February 4th, 2021
AdventHealth Sees Number of Hospitalized Patients DropFebruary 4th, 2021
Join now to see all